Viking Therapeutics stock is trading -31.5% below its average target price of $113.91 after marking a 6.6% during today's morning session. Analysts are giving the Mid-Cap Pharmaceutical company an average rating of buy and target prices ranging from $90.0 to $138.0 per share.
The stock has an unusually large proportion of its shares sold short at 17.3%, and a short ratio of 5.25. Since 6.0% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 74.9% of Viking Therapeutics's shares being owned by this investor type.
Institutions Invested in Viking Therapeutics
Date Reported | Holder | Percentage | Shares | Value |
---|---|---|---|---|
2024-06-30 | FMR, LLC | 15% | 16,540,281 | $1,290,638,106 |
2024-06-30 | Vanguard Group Inc | 9% | 10,097,337 | $787,895,193 |
2024-06-30 | Blackrock Inc. | 5% | 6,026,131 | $470,218,994 |
2024-06-30 | State Street Corporation | 5% | 5,122,428 | $399,703,050 |
2024-06-30 | JP Morgan Chase & Company | 2% | 2,251,671 | $175,697,885 |
2024-06-30 | Geode Capital Management, LLC | 2% | 1,859,082 | $145,064,166 |
2024-06-30 | Susquehanna International Group, LLP | 1% | 1,404,715 | $109,609,909 |
2024-06-30 | Pictet Asset Management Holding SA | 1% | 1,381,374 | $107,788,611 |
2024-06-30 | Viking Global Investors, L.P. | 1% | 1,354,450 | $105,687,731 |
2024-09-30 | Perpetual Ltd. | 1% | 1,269,152 | $99,031,929 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Viking Therapeutics.